The study of effects of additional beraprost on the amelioration and retention of retinal and choroidal circulation after ranibizumab treatment in age-related macular degeneration.

The study of effects of additional beraprost on the amelioration and retention of retinal and choroidal circulation after ranibizumab treatment in age-related macular degeneration. - The study of additional beraprost in age-related macular degeneration

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006869

Enrollment

Registered

2011-12-10

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

Take orally of beraprost sodium 60 microgram per day for 6 months after surgery No drug.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Intravireous injection of ranibizumab for age related macular degeneration monthly for 3 months and since then become composed.

Exclusion criteria

Exclusion criteria: glaucoma,hypertension,past history or risk of stroke, bleeding, tendency of bleeding, other anticoagulant

Design outcomes

Primary

Measure	Time frame
after 6 months from beginning of the medication	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026